Kate Cwynarski

Nov 11, 2024 | nature.com | Kate Cwynarski |Mathieu Ferrari |Paul M Maciocia

AbstractRelapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens that discriminate malignant from normal T cells, thus avoiding severe immunosuppression consequent to depletion of the entire T cell compartment.

Jan 29, 2024 | thelancet.com | Elizabeth Phillips |Kate Cwynarski

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Dec 11, 2023 | nejm.org | David Cairns |David J. Allsup |Kate Cwynarski |Andrew Pettitt

December 10, 2023 DOI: 10.1056/NEJMoa2310063 AbstractThe combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib–venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine–cyclophosphamide–rituximab (FCR) is unclear.

Jun 9, 2023 | onlinelibrary.wiley.com | Jahanzaib Khwaja |Kate Cwynarski

Older/unfit patients The addition of rituximab to MTX based regimens in 38/94 patients with isolated SCNSL was associated with improved OS, even after adjustment for age >60, ECOG PS > 1, multiagent MTX versus MTX alone, time to SCNSL and CNS-direct radiotherapy, and may be considered a less intensive option.47 Other combinations for patients with CNS lymphoma who are not ASCT-eligible include rituximab plus MTX and temozolomide54 or novel agents.